A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 861 participants.
Also called NCT03990363
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 861 participants
- Sponsor
- Registry
-
NCT03990363
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, France, Hungary, Israel, Italy, Mexico, Poland, Romania, Slovakia, South Africa, Spain
- Registry status
- Completed
Technical summary
Registry record NCT03990363. Randomized; quadruple masking; primary purpose treatment. Start 2019-07-23 (actual); primary completion 2021-11-22 (actual). Results posted on 2023-03-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
- Acronym
- SAPPHIRE
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Verinurad
- Intervention (Drug)
- Allopurinol
- Intervention (Drug)
- Placebo for Verinurad
- Intervention (Drug)
- Placebo for Allopurinol
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct03990363- Content hash
546e101a5a4820f5a90f776e8bcaf4e2c04985b617aa3bbcf83a8ee487494fb0